推荐产品
product name
阿西替尼, ≥98% (HPLC)
化驗
≥98% (HPLC)
形狀
powder
顏色
white to tan
溶解度
DMSO: ≥8 mg/mL
儲存溫度
room temp
SMILES 字串
CNC(=O)c1ccccc1Sc2ccc3c(\C=C\c4ccccn4)n[nH]c3c2
InChI
1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+
InChI 密鑰
RITAVMQDGBJQJZ-FMIVXFBMSA-N
基因資訊
human ... FLT1(2321) , FLT4(2324) , KDR(3791)
應用
阿昔替尼已被用作血管内皮生长因子 (VEGF) 受体酪氨酸激酶抑制剂 (TKI) ，以研究其对肾癌细胞体外增殖的影响。此外，在调理水 (CW) 中维持的脱氯胚胎中，它还用于抑制肠系膜上动脉 (AMA) 血管生成。
生化／生理作用
阿昔替尼 (AG-013736) 是一种口服强效（皮摩）选择性酪氨酸激酶抑制剂，可阻断VEGF受体 1、2 和 3。该药物可通过内皮型一氧化氮合成酶、Akt和细胞外信号调节激酶，阻断VEGF介导的内皮细胞存活、血管形成及下游信号传导。
特點和優勢
这种化合物是激酶磷酸酶生物学研究的特色产品。点击此处发现更多特色激酶磷酸酶生物产品。在sigma.com/discover-bsm可了解更多关于生物活性小分子的其他研究领域。
法律資訊
根据辉瑞公司的协议出售，用于研究目的。
訊號詞
Warning
危險聲明
危險分類
Acute Tox. 4 Oral - Aquatic Acute 1
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
其他客户在看
Hypoxic 3D in vitro culture models reveal distinct resistance processes to TKIs in renal cancer cells
Bielecka Z, et al.
Cell & Bioscience, 7(1), 71-71 (2017)
Ana Carolina Monteiro et al.
Molecular oncology, 13(6), 1433-1449 (2019-05-10)
The high mortality rate of melanoma is broadly associated with its metastatic potential. Tumor cell dissemination is strictly dependent on vascularization; therefore, angiogenesis and lymphangiogenesis play an essential role in metastasis. Hence, a better understanding of the players of tumor
Renin expression in developing zebrafish is associated with angiogenesis and requires the Notch pathway and endothelium
Rider S, et al.
American Journal of Physiology: Renal Physiology, 309(6), F531-F539 (2015)
Fatma Demircan Yildirim et al.
Medycyna pracy, 71(6), 649-663 (2020-10-28)
About 8 million healthcare workers in the USA are potentially exposed to hazardous drugs or their toxic metabolites over a long period of time despite the fact that both the Occupational Safety and Health Administration and the European Parliament recommend
Akira Kazama et al.
Oncology reports, 46(4) (2021-09-02)
The selection of effective therapeutic agents is critical for improving the survival of patients with renal cell carcinoma (RCC). The aim of the present study was to develop an ex vivo drug testing assay using patient‑derived tumor organoid (TO) cultures. For this purpose
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门